

## Editorials

- Preventing Deaths from Methotrexate Overdose**  
*E. Etchells* . . . . . 1853
- Use of Low-Dose Glucocorticoids and the Risk of Cardiovascular Morbidity and Mortality in Rheumatoid Arthritis: What Is the True Direction of Effect?**  
*J.M. Davis III, H. Maradit-Kremers, S.E. Gabriel* . . . . . 1856
- Steroids for Rheumatoid Arthritis: The Honeymoon Revisited (Once Again)**  
*L. Caplan, A.S. Russell, F. Wolfe* . . . . . 1863
- Malignancy and Rheumatic Disease — A Real Association?** *S. Chambers, D. Isenberg* . . . . . 1866
- Bone Mineral Content versus Bone Density in a Population with Osteoarthritis: A New Twist to the Controversy?** *H. McDonald-Blumer* . . . . . 1868
- ADAM Proteins as Therapeutic Targets in Loosening of Total Hip Replacement Implants?**  
*S. Naus, J.W. Bartsch* . . . . . 1870
- Race, Scleroderma, and Survival: Why Is There a Difference?** *M.D. Mayes* . . . . . 1873

## Articles

- Household Income and Earnings Losses Among 6,396 Persons with RA**  
*F. Wolfe, K. Michaud, H.K. Choi, R. Williams* . . . . . 1875
- Autoimmune Disease Is a Risk Factor for the Development of Non-Hodgkin's Lymphoma**  
*J. Cuttner, H. Spiera, K. Troy, S. Wallenstein* . . . . . 1884
- Demographic and Clinical Factors Associated with In-Hospital Death Among Patients with SSc**  
*P.J. Nietert, R.M. Silver, H.C. Mitchell, S.R. Shaftman, B.C. Tilley* . . . . . 1888
- Distinct Expression of Adhesion Molecules on Skin Fibroblasts from Patients with Diffuse and Limited SSc. A Pilot Study**  
*F. Iannone, M. Matucci-Cerinic, P.C.F. Falappone, S. Guiducci, M. Cinelli, O. Distler, G. Lapadula* . . . . . 1893
- The Cochrane Review of Physiotherapy Interventions for AS** *H. Dagfinrud, T.K. Kvien, K.B. Hagen* . . . . . 1899
- IL-1 and NF- $\kappa$ B Polymorphisms in AS in Canada and Korea** *T-H. Kim, M.A. Stone, P. Rahman, et al.* . . . . . 1907

- Etanercept Exerts Beneficial Effects on Articular Cartilage Biomarkers of Degradation and Turnover in Patients with AS** *W.P. Maksymowych, A.R. Poole, L. Hiebert, et al.* . . . . . 1911
- Prevalence, Disease Manifestations, and Treatment of PsA in Western Norway** *T.M. Madland, E.M. Apalset, A.E. Johannessen, B. Rossebö, J.G. Brun* . . . . . 1918
- Factors Associated with Musculoskeletal Disability and Chronic Renal Failure in Clinically Diagnosed Primary Gout** *J. Alvarez-Nemegyei, J.C. Cen-Pisté, M. Medina-Escobedo, S. Villanueva-Jorge* . . . . . 1923
- Clinical Effects of Intraarticular Injection of High Molecular Weight Hyaluronan (Orthovisc®) in OA of the Knee: A Randomized, Controlled, Multicenter Trial**  
*D. Neustadt, J. Caldwell, M. Bell, J. Wade, J. Gimbel* . . . . . 1928
- The Genetic Contribution and Relevance of Knee Cartilage Defects: Case-Control and Sib-Pair Studies**  
*C. Ding, F. Cicuttini, F. Scott, J. Stankovich, H. Cooley, G. Jones* . . . . . 1937
- Increased Expression and Processing of ADAM 12 (Meltrin- $\alpha$ ) in Osteolysis Associated with Aseptic Loosening of Total Hip Replacement Implants**  
*G. Ma, M. Ainola, M. Liljeström, et al.* . . . . . 1943
- Increased Bone Mineral Content But Not BMD in the Hip in Surgically Treated Knee and Hip OA**  
*L. Sandini, J.P.A. Arokoski, J.S. Jurvelin, H. Kröger* . . . . . 1951
- Comparative Effects of 2 Antioxidants, Selenomethionine and Epigallocatechin-Gallate, on Catabolic and Anabolic Gene Expression of Articular Chondrocytes**  
*R. Andriamanalijaona, C. Baugé, E. Renard, et al.* . . . . . 1958
- Safety and Tolerability of Oral Daily and Intermittent Ibandronate Are Not Influenced by Age**  
*M.P. Ettinger, D. Felsenberg, S.T. Harris, et al.* . . . . . 1968
- Efficacy of Milnacipran in Patients with FM**  
*R.M. Gendreau, M.D. Thorn, J.F. Gendreau, et al.* . . . . . 1975
- Pediatric Rheumatology**
- Eye Findings in Patients with JDM** *J.D. Akikusa, D.K. Tennankore, A.V. Levin, B.M. Feldman* . . . . . 1986
- Longitudinal Analysis of a Pediatric Rheumatology Clinic Population** *A.M. Rosenberg* . . . . . 1992

*Contents continued opposite inside back cover . . .*

---

## Case Reports

**Poststreptococcal Reactive Arthritis with Thoracic Spine Involvement in an Adult** *A. Alexopoulou, S.P. Dourakis, N.D. Stamoulis, D. Vassilopoulos, A.J. Archimandritis* . . . . . 2002

**Synovial Sarcoma of the Foot Mimicking Acute Gouty Arthritis**  
*Y. Du, S. Pullman-Moore, H.R. Schumacher* . . . . . 2006

**Deaths Following MTX Overdoses by Medical Staff**  
*I. Sinicina, B. Mayr, G. Mall, W. Keil* . . . . . 2009

## OMERACT 7

**International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials, Asilomar, California, USA, May 8-12, 2004**

**Introduction** *C.V. Strand, L.S. Simon, P. Tugwell, P. Brooks, M. Boers* . . . . . 2014

**Minimal Disease Activity for RA: A Preliminary Definition** *G.A. Wells, M. Boers, B. Shea, et al* . . . . . 2016

**Minimal Clinically Important Difference, Low Disease Activity State, and Patient Acceptable Symptom State: Methodological Issues**  
*F. Tubach, G.A. Wells, P. Ravard, M. Dougados* . . . . . 2025

**Challenges and Progress in Adverse Event Ascertainment and Reporting in Clinical Trials**  
*M.N.D. Lassere, K.R. Johnson, for the OMERACT Drug Safety Working Group* . . . . . 2030

**Generic Patient Self-Report and Investigator Report Instruments of Therapeutic Safety and Tolerability**  
*M.N.D. Lassere, K.R. Johnson, S. Van Santen, et al* . . . . . 2033

**Standardized Assessment of Adverse Events in Rheumatology Clinical Trials: Summary of the OMERACT 7 Drug Safety Module Update**  
*M.N.D. Lassere, K.R. Johnson, M. Boers, et al* . . . . . 2037

**Application of the OMERACT Filter to Scoring Methods for MRI of the Sacroiliac Joints and the Spine. Recommendations for a Research Agenda at OMERACT 7** *D.M.F.M. van der Heijde, R.B.M. Landewé, K-G.A. Hermann, et al* . . . . . 2042

**Selection of a Method for Scoring Radiographs for AS Clinical Trials, by the Assessment in AS Working Group and OMERACT** *D.M.F.M. van der Heijde, R.B.M. Landewé, and the ASAS Working Group* . . . . . 2048

**Scoring Sacroiliac Joints by MRI. A Multiple-Reader Reliability Experiment** *R.B.M. Landewé, K-G.A. Hermann, D.M.F.M. van der Heijde, et al* . . . . . 2050

**MRI of Inflammatory Lesions in the Spine in AS Clinical Trials: Is Paramagnetic Contrast Medium Necessary?** *K-G.A. Hermann, R.B.M. Landewé, J. Braun, D.M.F.M. van der Heijde* . . . . . 2056

## Correspondence

**Treating Leukocytoclastic Vasculitis Associated with Etanercept Therapy. Is It Necessary to Stop Etanercept?** *A. Juan, B. Ribas, C. Nadal, I. Ros* . . . . . 2061

**Reply** *N. Mohan* . . . . . 2061

## Letter

**CTLA-4 -1661A/G and -1772T/C Dimorphisms in Japanese Patients with SLE**  
*F. Takeuchi, S. Kuwata, M. Mori* . . . . . 2062

## Correction

**Fibromyalgia Syndrome: Review of Clinical Presentation, Pathogenesis, Outcome Measures, and Treatment** *P. Mease* . . . . . 2063

**Meetings in Rheumatology** . . . . .